Long-term cost-effectiveness of home versus clinic-based management of chronic heart failure: the WHICH? study

References

• Roger VL. Epidemiology of heart failure. Circ Res 2013;113:646-59
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013;62:e147-239
   PubMed Web of Science ®Google Scholar
• Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail 2001;3:283-91
   PubMed Web of Science ®Google Scholar
• Stewart S. Financial aspects of heart failure programs of care. Eur J Heart Fail 2005;7:423-8
   PubMed Web of Science ®Google Scholar
• Oddone EZ, Weinberger M, Horner M, et al. Classifying general medicine readmissions. Are they preventable? Veterans affairs cooperative studies in health services group on primary care and hospital readmissions. J Gen Intern Med 1996;11:597-607
   PubMed Web of Science ®Google Scholar
• Yu DSF, Thompson DR, Lee DTF. Disease management programmes for older people with heart failure: crucial characteristics which improve post-discharge outcomes. Eur Heart J 2006;27:596-612
   PubMed Web of Science ®Google Scholar
• Whellan D, Hasselblad V, Peterson E, et al. Meta-analysis and review of heart failure disease management randomized controlled clinical trials. Am Heart J 2005;149:722-9
   PubMed Web of Science ®Google Scholar
• Feltner C, Jones CD, Cené CW, et al. Transitional care interventions to prevent readmissions for persons with heart failure. A systematic review and meta-analysis. Ann Intern Med 2014;160:774-84
   PubMed Web of Science ®Google Scholar
• Maru S, Byrnes J, Carrington MJ, et al. Systematic review of trial-based analyses reporting the economic impact of heart failure management programs compared with usual care. Eur J Cardiovasc Nurs 2016;15:82-90
   PubMed Web of Science ®Google Scholar
• Del Sindaco D, Pulignano G, Minardi G, et al. Two-year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure. J Cardiovasc Med (Hagerstown) 2007;8:324-9
   PubMed Web of Science ®Google Scholar
• Pulignano G, Del Sindaco D, Di Lenarda A, et al. Usefulness of frailty profile for targeting older heart failure patients in disease management programs: a cost-effectiveness, pilot study. J Cardiovasc Med (Hagerstown) 2010;11:739-47
   PubMed Web of Science ®Google Scholar
• Maru S, Byrnes J, Carrington MJ, et al. Cost-effectiveness of home versus clinic-based management of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized trial cohort—The WHICH? study (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care). Int J Cardiol 2015;201:368-75
   PubMed Web of Science ®Google Scholar
• Latimer NR. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making 2013;33:743-54
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton K, Sculpher M, et al. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006
   Google Scholar
• Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, Inc; 1996
   Google Scholar
• Inglis SC, Pearson S, Treen S, et al. Extending the horizon in chronic heart failure: effects of multidisciplinary, home-based intervention relative to usual care. Circulation 2006;114:2466-73
   PubMed Web of Science ®Google Scholar
• Holland R, Battersby J, Harvey I, et al. Systematic review of multidisciplinary interventions in heart failure. Heart 2005;91:899-906
   PubMed Web of Science ®Google Scholar
• Stewart S, Carrington MJ, Marwick T, et al. The WHICH? trial: rationale and design of a pragmatic randomized, multicentre comparison of home- vs clinic-based management of chronic heart failure patients. Eur J Heart Fail 2011;13:909-16
   PubMed Web of Science ®Google Scholar
• Stewart S, Carrington MJ, Marwick TH, et al. Impact of home versus clinic-based management of chronic heart failure: The WHICH? (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care) multicenter, randomized trial. J Am Coll Cardiol 2012;60:1239-48
   PubMed Web of Science ®Google Scholar
• Stewart S, Carrington MJ, Horowitz JD, et al. Prolonged impact of home versus clinic-based management of chronic heart failure: extended follow-up of a pragmatic, multicentre randomized trial cohort. Int J Cardiol 2014;174:600-10
   PubMed Web of Science ®Google Scholar
• Sonnenberg F, Beck J. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38
   PubMed Web of Science ®Google Scholar
• Stewart S, Ekman I, Ekman T, et al. Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004). Circ Cardiovasc Qual Out 2010;3:573-80
   PubMed Web of Science ®Google Scholar
• Chan DC, Heidenreich PA, Weinstein MC, et al. Heart failure disease management programs: a cost-effectiveness analysis. Am Heart J 2008;155:332-8
   PubMed Web of Science ®Google Scholar
• Gohler A, Conrads-Frank A, Worrell SS, et al. Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure. Eur J Heart Fail 2008;10:1026-32
   PubMed Web of Science ®Google Scholar
• Moertl D, Steiner S, Coyle D, et al. Cost-utility analysis of NT-proBNP-guided multidisciplinary care in chronic heart failure. Int J Technol Assess Health Care 2013;29:3-11
   PubMed Web of Science ®Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3. Value Health 2012;15:812-20
   PubMed Web of Science ®Google Scholar
• Alter DA, Ko DT, Tu JV, et al. The average lifespan of patients discharged from hospital with heart failure. J Gen Intern Med 2012;27:1171-9
   PubMed Web of Science ®Google Scholar
• Australian Government DoH. The pharmaceutical benefits advisory committee (PBAC) guidelines. Version 4.4; 2013. http://www.pbac.pbs.gov.au/information/table-of-contents.html. Accessed November 19, 2014
   Google Scholar
• Australian Government. Best practice regulation handbook. Canberra: Australian Government; 2007. p 140. http://regulationbodyofknowledgeorg/wp-content/uploads/2013/03/AustralianGovernment_Best_Practice_Regulationpdf. Accessed August 3, 2015
   Google Scholar
• Campbell and Cochrane Economics Methods Group and the Evidence for Policy and Practice Information and Coordinating Centre. ‘CCEMG – EPPI-Centre Cost Converter’ (v.1.4). 2015, http://eppi.ioe.ac.uk/costconversion/default.aspx. Accessed February 15, 2016
   Google Scholar
• Allison P. Survival analysis using SAS: a practical guide. Cary, NC: SAS Publishing; 1995
   Google Scholar
• Australian Bureau of Statistics. Life tables 2011–2013 (cat. no. 3302.0). Released on 06/11/2014. http://www.abs.gov.au/ausstats/[email protected]/mf/3302.0.55.001. Accessed February 15, 2016
   Google Scholar
• Johnston K, Gray A, Moher M, et al. Reporting the cost-effectiveness of interventions with nonsignificant effect differences: example from a trial of secondary prevention of coronary heart disease. Int J Technol Assess Health Care 2003;19:476-89
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher M, Torrance G, et al. Methods for the economic evaluation of health care programmes. 3rd edn. New York: Oxford University Press; 2005
   Google Scholar
• Chim L, Kelly PJ, Salkeld G, et al. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia? Pharmacoeconomics 2010;28:463-75
   PubMed Web of Science ®Google Scholar
• George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001;19:1103-9
   PubMed Web of Science ®Google Scholar
• Harris AH, Hill SR, Chin G, et al. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994–2004. Med Decis Making 2008;28:713-22
   PubMed Web of Science ®Google Scholar
• Yu J, Shah BM, Ip EJ, et al. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California. J Manag Care Pharm JMCP 2013;19:102-14
   PubMed Web of Science ®Google Scholar
• Rascati KL. Essentials of pharmacoeconomics. 2nd edn. Philadelphia: Lippincott Williams & Wilkins; 2013
   Google Scholar
• Gheorghiade M, Vaduganathan M, Fonarow GC, et al. Rehospitalization for heart failure problems and perspectives. J Am Coll Cardiol 2013;61:391-403
   PubMed Web of Science ®Google Scholar
• Metra M, Gheorghiade M, Bonow RO, et al. Postdischarge assessment after a heart failure hospitalization: the next step forward. Circulation 2010;122:1782-5
   PubMed Web of Science ®Google Scholar
• Greene SJ, Fonarow GC, Vaduganathan M, et al. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol 2015;12:220-9
   PubMed Web of Science ®Google Scholar
• Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term outcomes among medicare patients hospitalized for heart failure, 1993–2006. JAMA 2010;303:2141-7
   PubMed Web of Science ®Google Scholar
• Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013;309:355-63
   PubMed Web of Science ®Google Scholar
• Maru S, Byrnes J, Carrington MJ, et al. Cost-effectiveness of home versus clinic-based management of chronic heart failure: extended follow-up of a pragmatic, multicentre randomized trial cohort; the WHICH? study (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care). Int J Cardiol 2015;201:368-75
   PubMed Web of Science ®Google Scholar
• Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation 2012;126:501-6
   PubMed Web of Science ®Google Scholar
• Hirst NG, Whitty JA, Synnott RL, et al. Predictors of government subsidized pharmaceutical use in patients with diabetes or cardiovascular disease in a primary care setting: evidence from a prospective randomized trial. J Med Econ 2011;14:698-704
   PubMedGoogle Scholar